Managing Hereditary Cancer Syndromes

---
name: managing-hereditary-cancer-syndromes
language: en
description: Guides hereditary cancer risk assessment with genetic testing criteria and management recommendations. Use when evaluating hereditary cancer risk, ordering genetic testing, or managing high-risk patients.
tags:
  - management
  - oncology
  - risk
  - patient-care
metadata:
  author: casemark
  practice_areas:
    - Medical Oncology
    - Hematology-Oncology
    - Radiation Oncology
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Hereditary Cancer Syndromes

Guides hereditary cancer risk assessment with genetic testing criteria and management recommendations.

## Why This Skill Exists

Approximately 5–10% of all cancers are caused by inherited germline mutations. Identifying hereditary cancer syndromes has direct therapeutic implications: BRCA1/2-mutated cancers respond to PARP inhibitors and platinum chemotherapy; Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) tumors are MSI-high and respond to immune checkpoint inhibitors; Li-Fraumeni syndrome requires intensive multi-organ surveillance. Beyond the index patient, identifying a hereditary syndrome triggers cascade testing of at-risk family members and potentially life-saving risk-reduction strategies.

NCCN Genetic/Familial High-Risk Assessment guidelines define testing criteria and management recommendations. ASCO recommends genetic counseling and testing when results will influence management of the patient or family members. Failure to identify hereditary cancer syndromes exposes patients to inferior treatment selection, family members to unrecognized cancer risk, and institutions to malpractice liability. Universal tumor screening for Lynch syndrome in all colorectal and endometrial cancers is now standard of care per NCCN guidelines.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the patient's cancer diagnosis (type, stage, age at diagnosis, histology)? (Default: [VERIFY])
2. What is the patient's family cancer history (three-generation pedigree including cancer type, age at diagnosis, and ancestry)? (Default: collect comprehensive family history)
3. Has any family member had genetic testing? If yes, provide results. (Default: assess)
4. Has tumor testing (MSI, MMR IHC, somatic genomic profiling) been performed? (Default: review)
5. What is the patient's ancestry (relevant for founder mutations: Ashkenazi Jewish, Icelandic, etc.)? (Default: document)
6. What is the patient's age at diagnosis? (Default: document — young age increases hereditary probability)
7. Has the patient been referred to genetic counseling? (Default: assess need)
8. What is the purpose of this assessment (treatment selection, risk management, family planning, cascade testing)? (Default: specify)

### Documents to Request

- Three-generation family cancer pedigree
- Prior genetic testing results (patient and family members)
- Tumor molecular profiling results (somatic NGS, MSI testing, MMR IHC)
- Pathology report with histologic features (e.g., medullary features in CRC, triple-negative breast cancer)
- Risk assessment model outputs (Tyrer-Cuzick, BRCAPro, PREMM5, MMRpro) if available
- Genetic counseling documentation
- Insurance pre-authorization for genetic testing if needed
- NCCN Genetic/Familial High-Risk Assessment guideline for relevant syndromes

---

## Step 1: Identify Patients Who Meet Testing Criteria

**NCCN criteria for BRCA1/2 genetic testing (selected triggers):**
- Breast cancer diagnosed ≤50 years of age
- Triple-negative breast cancer diagnosed ≤60 years of age
- Two primary breast cancers (bilateral or ipsilateral) with first diagnosed ≤50
- Male breast cancer at any age
- Ovarian/fallopian tube/primary peritoneal cancer at any age
- Pancreatic cancer with Ashkenazi Jewish ancestry or ≥1 close relative with breast/ovarian/pancreatic/prostate cancer
- Metastatic prostate cancer (for PARP inhibitor eligibility)
- Known BRCA1/2 mutation in the family
- Ashkenazi Jewish ancestry with breast cancer at any age

**Lynch syndrome (universal tumor screening):**
- All colorectal cancers: perform MSI testing AND/OR MMR IHC (MLH1, MSH2, MSH6, PMS2)
- All endometrial cancers: perform MMR IHC
- If MLH1 loss: test for MLH1 promoter hypermethylation ± BRAF V600E — if both present, likely sporadic (not Lynch)
- If any MMR protein loss (without MLH1 hypermethylation) or MSI-high: refer for germline testing

**Other hereditary syndromes to consider:**

| Syndrome | Gene(s) | Associated Cancers | Key Features |
|---------|---------|-------------------|-------------|
| Li-Fraumeni | TP53 | Breast, sarcoma, brain, adrenocortical, leukemia | Multiple primaries, very young onset, adrenocortical carcinoma |
| Cowden | PTEN | Breast, thyroid, endometrial, renal | Macrocephaly, mucocutaneous lesions, thyroid nodules |
| FAP | APC | Colorectal, duodenal, thyroid, desmoid | >100 colorectal polyps, polyps in teens |
| Attenuated FAP | APC (select mutations), MUTYH (biallelic) | Colorectal | 10–99 adenomatous polyps |
| CDH1 | CDH1 | Diffuse gastric cancer, lobular breast cancer | Family history of diffuse gastric cancer |
| VHL | VHL | Renal cell (clear cell), pheochromocytoma, CNS hemangioblastoma | Multiple bilateral renal tumors at young age |
| MEN1/MEN2 | MEN1, RET | Parathyroid, pituitary, pancreatic NET (MEN1); medullary thyroid, pheo (MEN2) | Multiple endocrine tumors |
| Hereditary diffuse gastric cancer | CDH1 | Diffuse gastric, lobular breast | Signet ring cell histology in family |

---

## Step 2: Facilitate Genetic Counseling and Testing

**Pre-test genetic counseling must include:**
1. Assessment of personal and family history
2. Risk assessment model calculation when applicable
3. Discussion of hereditary cancer syndromes relevant to the patient's presentation
4. Explanation of testing options (single gene, multi-gene panel, tumor-normal paired)
5. Discussion of possible results: positive (pathogenic/likely pathogenic), negative, VUS
6. Implications of results for treatment, surveillance, risk reduction, and family members
7. Psychosocial assessment (impact on insurance, employment — GINA protections and limitations)
8. Informed consent documentation

**Testing platform selection:**
- **Multi-gene panel testing** is now standard — panels of 30–80+ genes cover most actionable hereditary syndromes simultaneously
- **Single-gene testing** may be appropriate when a known familial mutation exists (cascade testing)
- **Tumor-normal paired testing** can distinguish somatic from germline variants for mutations identified on somatic profiling

---

## Step 3: Interpret Results and Determine Clinical Implications

**Pathogenic/Likely Pathogenic variant identified:**

| Finding | Treatment Implications | Surveillance Implications |
|---------|----------------------|--------------------------|
| BRCA1/2 | PARP inhibitors (olaparib, talazoparib, rucaparib); platinum sensitivity | Breast MRI annually starting age 25; consider risk-reducing mastectomy; risk-reducing salpingo-oophorectomy age 35–40 (BRCA1) or 40–45 (BRCA2) |
| Lynch (MLH1/MSH2/MSH6/PMS2) | Checkpoint inhibitor eligibility (MSI-H/dMMR); aspirin chemoprevention | Colonoscopy every 1–2 years starting age 20–25; consider risk-reducing hysterectomy after childbearing |
| TP53 (Li-Fraumeni) | Avoid radiation therapy when possible | Whole-body MRI annually; breast MRI annually age 20+; comprehensive surveillance protocol |
| CDH1 | Consider prophylactic total gastrectomy | Annual breast MRI for lobular breast cancer surveillance |
| APC (FAP) | — | Colonoscopy annually starting age 10–12; colectomy when polyps unmanageable |
| PALB2 | PARP inhibitor eligibility; platinum sensitivity | Breast MRI annually starting age 30; consider risk-reducing mastectomy |
| ATM, CHEK2 | Emerging targeted therapy data | Enhanced breast surveillance (CHEK2: annual breast MRI); CHEK2: colonoscopy starting age 40 |

**VUS (Variant of Uncertain Significance):**
- Do NOT change clinical management based on a VUS
- Inform the patient that the variant may be reclassified over time
- Recommend periodic check with the testing laboratory for reclassification updates
- Do NOT offer cascade testing to family members for a VUS

**Negative result (no pathogenic variant found):**
- If a known familial mutation was tested and not found: true negative — patient at population risk
- If no known familial mutation: uninformative negative — patient may still have an undetected hereditary predisposition. Continue risk-based management per family history.

---

## Step 4: Coordinate Cascade Testing and Family Risk Management

When a pathogenic variant is identified:

1. **Inform the patient** about the implications for biological relatives
2. **Provide materials** for the patient to share with at-risk family members (letters, testing information)
3. **At-risk first-degree relatives** should be offered genetic counseling and testing for the identified variant
4. **Develop a surveillance and risk-reduction plan** for each mutation-positive family member per NCCN guidelines
5. **Document family communication** — note that the patient has been counseled to inform relatives; the provider cannot contact family members directly without consent

**Risk-reduction strategies by syndrome:**
- BRCA1/2: risk-reducing bilateral mastectomy (reduces breast cancer risk by ~90%), risk-reducing bilateral salpingo-oophorectomy (reduces ovarian cancer risk by ~80% and breast cancer risk by ~50% if premenopausal)
- Lynch syndrome: risk-reducing hysterectomy and bilateral salpingo-oophorectomy after childbearing; aspirin 325–600mg daily for colorectal cancer risk reduction
- FAP: prophylactic colectomy (total proctocolectomy or ileal pouch-anal anastomosis) when polyp burden is unmanageable
- CDH1: prophylactic total gastrectomy recommended for confirmed carriers due to >70% lifetime risk of diffuse gastric cancer

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Were NCCN genetic testing criteria applied systematically to determine testing eligibility?
2. Was pre-test genetic counseling conducted and documented per NCCN guidelines?
3. Are pathogenic variants distinguished from VUS in the clinical recommendations?
4. Have treatment implications (PARP inhibitors, immunotherapy eligibility, radiation avoidance) been documented for identified mutations?
5. Has cascade testing been recommended for at-risk family members?

---

## Quality Audit

- [ ] Three-generation family cancer pedigree documented
- [ ] NCCN genetic testing criteria applied and met
- [ ] Pre-test genetic counseling conducted and documented
- [ ] Appropriate testing platform selected (multi-gene panel vs. single-gene)
- [ ] Results classified correctly (pathogenic, likely pathogenic, VUS, benign)
- [ ] VUS explicitly noted as not actionable for clinical decisions
- [ ] Treatment implications documented for pathogenic variants (PARP inhibitors, platinum sensitivity, radiation avoidance)
- [ ] Enhanced surveillance plan documented per NCCN guidelines for the specific syndrome
- [ ] Risk-reduction options discussed and patient preferences documented
- [ ] Cascade testing recommended to patient with materials to share with family
- [ ] Universal tumor screening performed for Lynch syndrome in all CRC and endometrial cancers
- [ ] Germline testing recommended when somatic profiling identifies potential germline variants (BRCA1/2, MMR genes)
- [ ] Psychosocial support and genetic counseling follow-up arranged
- [ ] GINA protections and limitations discussed regarding insurance and employment

---

## Guidelines

- Universal MSI/MMR testing should be performed on ALL colorectal and endometrial cancers regardless of age or family history — this is NCCN standard of care
- A VUS is NOT a positive result — do not alter treatment, surveillance, or family testing based on a VUS
- Genetic testing should be offered to the index cancer patient first (not an unaffected family member) whenever possible — a negative result in an unaffected person is uninformative
- For patients with metastatic cancer where PARP inhibitor therapy is being considered, germline BRCA testing should not delay treatment initiation — order expedited testing
- Li-Fraumeni syndrome (TP53 germline mutations) contraindicates radiation therapy when alternatives exist — radiation increases secondary malignancy risk in these patients
- Ashkenazi Jewish ancestry is an independent criterion for BRCA1/2 testing regardless of family history — three founder mutations (BRCA1 185delAG, BRCA1 5382insC, BRCA2 6174delT) account for ~2.5% carrier frequency
- MLH1 promoter hypermethylation with BRAF V600E in colorectal cancer is almost always sporadic, not Lynch syndrome — do not proceed to germline testing in these cases
- Genetic testing technology changes rapidly — panels expand and VUS are reclassified. Recontact testing laboratories periodically for updated variant classifications.